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NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANT (NASCT) 
WITH UNRELATED CORD BLOOD AND MATCHED FAMILY DONORS IN 
CHILDREN AND ADOLESCENTS 
Satwmfi, P.; Ita~v'isoJ~, L.; De/Tovo, G.; Bt'adley, 3/[.; Yamashi~'o, D.; 
Ggr~vin, .7.; Skd*dtt, D.; CheTtng, }~; vcm de Ue'n, C.; Besmze~'tjzy, 04 
HTischhover, C.; ~'Vo]o~11i~', K.; Geo'~'ge, D.; Cairo, IV[.S. ChilclreJT's 
Hospital of New Ym'te PresbyteHm~, New Yo1"k, NK 
NASCTs are successful in establishing durable grafts from both 
matched family and unrelated adult donors while substantially reduc- 
ing regimen related toxicity (Slavin et al, Blood: 99:1071, 2002; 
Chakravarty et al, Blood: 99:1071, 2002). There is little information 
about NASCT from UCB donor sources, which have a log less 
nuc/kg and CD34/kg. ~vVe report preliminary data in 11 recipients 
(<21 yrs) of NASCT. HLA typing was performed by serology class I 
(A&B) and high resolution DNTA typing class II (DRBI). Chianerism 
was performed by VNTR (D1580, D1757, D151 I, APO B) (Luhm et 
aI, Mol Diag 5; 129, 2000). Donor sources: 7 UCB (5 4/6, 2 5/6), 1 
Allo BM (6/6) and 3 Allo PBSC (2 6/6, i 5/6). NA conditioning: Flu 
150 mg/m 2, IV Bu 8 mg/kg and ATG 8 mg/kg (N=6); Flu 180 
mg/m ~, Bu 8-I6 mg/kg, alemtuzumab 54 mg/m 2 (N=2); Flu 150 
mg/m e, Cy 120 mg/kg, ATG 8 mg/kg (N=I); Flu 150 mg/m 2, Cy 600 
mg/m ~, ATG 8 mg/kg (N= 1 ); Flu 150 mg/m -~, Mel 140 mg/m 2, ATG 
(H) 90 mg/kg (N-I). GVHD prophylaxis: IV Tacrolimus 0.03 
mg/kg/day and mycophenolate mofetil 15 mg/kg q 12 hr. Demo- 
graphics: median age 13 (0.5-21) yrs; 4F, 7M; 2 CR2 HD, 1 PR2 HD, 
1 PD HD, 1 PR NHL, 1PD neuroblastoma, 1 PD ~tihns', 2 B-Thai, 
i WAS, 1 CP CML. UCB median uc/kg and CD34/kg 5.1 x 107/kg 
(1.6-9.5) and 2.1 x 105/kg (1.1-4.8), respectively. Allo BM/PBSC 
CD34/kg was 5.6 x 106/kg (5.0-6.3). Median time to ANC >500/mm 3 
x 2 D was 15 (3-29) days and platelet >20 Wmm* UNTX x 7 D was 22 
(6-170) days. Maximal donor chimerism following UCBT was 100% 
x 4 pts, 95% x 1 pt, 95% (2nd graft) x 1 pt, and 55% x 1 pt (died of 
PD day +79); AlloPBSC 100% x 3 pts and AlloBM 55% x 1 pt (day 
+60). Grade 1V Tox: 1 hepatic (LFTs, resolved), 1 encephalopathy 
(death), and 1 grade III-IV AGVHD (death). Infectious complica- 
tions: 6 bacterial sepsis (resolved), 1 systemic candidiasis (resolved), 
GI adenovirus (persistent) and 1 pulmonary adenovirus (death). Inci- 
dence of grade II-IV and III-1V AGVHD was 54.4% and 27.3%, 
respectively, and CGVHD was 9. 1%. Graft failure occurred in 1/11 
(B-Thal) (UCBT) that was successfully regrafted following full abla- 
tion. Probabilty of 1-yr overall survival is 60%. In sumnaary, these 
results uggest that NASCT especially from UCB HLA disparate 
donors in children and adolescent is feasible and tolerable (<10% GF) 
and restllts in 100% of patients having >50% mixed donor chimerism. 
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HLA-IDENTICAL ALLOGENEIC PERIPHERAL BLOOD STEM CELL 
TRANSPLANTATION IN HOMOZYGOUS [3 THALASSEMIA AND SEVERE 
THALASSEMIA/HEMOGLOBIN E DISEASE PATIENTS 
Pakaleasama, S.; Ho~ge~g, S.; ChaMHpoomkere, Fk~; ChuaT~smtrvit, 
A.; Sirachainmz, N.; ffoota*, S. Ramat/aibodi Hospital, Mahidol U~ive'm 
sity, Rajthevi, BaJgkok, Thai/mzd. 
Background: Thalassemia s the most common genetic disease in 
Thailand. Curative treatment with allogeneic bone marrow and 
cord blood transplantation has been reported. However, peripher- 
al blood stem cell transplantation (PBSCT) data in this disease is 
limited. Objective: To determine the outcome of 13 thalassemia 
major patients who underwent HLA-identical allogeneic PBSCT. 
Methods: We conducted a cohort study of allogeneic PBSCT in 
homozygous [3([3/13) thalassemia and severe 13 thalassemia/Hemo- 
globin E ([3/E) disease patients who had HLA-matched sibling 
donors. All patients received conditioning regimen including 
busulfan and cyclophosphamide (BU/CTX) except one received 
BU/CTX and antithymocyte globulin. Acute GVHD prophyla~s 
consisted of cyclosporin A (CSA) and methotrexate for 8 patients 
and CSA and mycophenolate motifil for 1 patient. Donors 
received G-CSF for 4 days before lenkapheresis collection. 
Results: Five 13/[3 and four severe [3/E diseases patients were stud- 
ied. The median age was 10 years (1.5 to 11 years). The median 
CD 34+ cells was 8.48 x 106 cells/kg recipient body weight. M1 
patients achieved myeloid and platelet engraftment with a median 
Poster  P resentat ions  - Sess ion  I I  
time of 15 days and 21 days respectively. Acute GVHD grade II- 
IV appeared in four patients (grade II = 3, grade IV = 1). Three 
patients developed chronic GVHD (limited = I, extensive = 2). All 
patients were alive with a median follow up time of i8 months (2- 
47 months). Neither graft failure nor graft rejection was observed 
in this study. Conclusion: Allogeneic PBSCT is feasible for chil- 
dren with 13 thalassemia major although GVHD was apparently 
high compared to BMT studies in Thais. 
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ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHILDREN 
WITH HEMATOLOGIC MALIGNANCIES 
Hale, G.A.; Cumm~g-hall~, ff.31.; Be71aim, E.; Heslop, H.E.; R)',n~ce, 
R.A.; Horwitz, E.M.; ToJTg, X.; SHvastava, D.K.; Leltng, ~'K; 
Woo&J'd, J.P.; Bowmml, L.C.; Ha,ldgvet#zgel, R. Hematology/OJ~colo- 
go;, St. Jade Child'lw~ 's Resemvh Hospital, Memphis, TN. 
Allogeneic BMT is potentially curative }'or patients with high 
risk or recurrent hematologic malignancy, in this series, we report 
249 children with ALL, AML, CML, or MDS who underwent 
allogeneic BMT at St. Jude Children's Research Hospital between 
1992-2000. The nmdian age at BMT was 11.2 years; 22 had 
received a prior autograft. 86 patients received unrelated onor 
(MUD) grafts matched at 6 HLA loci, 48 MUD grafts matched at 
5 HLA loci, 84 matched sibling (MSD) grafts and 31 mismatched 
family member (MMFM) grafts. The conditioning regimen 
included cytarabine, cyclophophamide, total body irradiation. 
ATG was provided to enhance the immunosuppression f r recipi- 
ents of MUD and MMFM grafts. MUD and MMFM grafts were 
depleted of T-lymphocytes using antibodies against CD6 and 
CD8 with rabbit complement. Grafts fi'om MSD were unmanipn- 
lated. Cyclosporine GVHD prophylaxis was given to all patients, 
and pe~toxifylline or short-course methotrexate was provided to 
MSD graft recipients. The cumulative incidence of grade 2-4 
acute GVHD was 23%; the cumulative chronic GVHD was 17%. 
The two year probability of disease-free (DFS) and overall sur- 
vival (OS) were 44% and 47%, respectively. The cumulative inci- 
dence of relapse was 25%; the cumulative incidence of regimen- 
related mortality was 35%. Favorable prognostic factors for OS 
included a diagnosis of CML, not having a secondary malignancy, 
receiving agraft matched at HLA class 1, younger patient age, and 
lower T-cell graft content. Favorable prognostic factors for DFS 
included not having a second malignancy, receiving a graft 
matched at HLA class I, and lower T-cell graft content. Probabil 
ities of DFS by donor status were as follows: MSD 46.8%, MUD 
matched at 6 HLA loci 46.2%, MUD matched at 5 HLA loci 
31.2%, and MMFM 25.4% (p=0.026). Recipients of MSD and 
MUD grafts matched at 6 HLA loci had similar outcomes; recipi- 
ents of NIMFM grafts and MUD grafts matched at 5 HLA loci 
had similar outcomes. These results suggest that MMFM donors 
may be preferred over MUD grafts matched at 5 HLA loci for 
patients lacking a MSD or MUD matched at 6 HLA loci. 
2O8 
A LIMITED SAMPLING STRATEGY (LSS) TO TARGET SYSTEMIC EXPO- 
SURE (SE) OF BUSULFEX (BUSULFAN) INJECTION (IVBU) IN PEDI- 
ATRIC PATIENTS (PEDS) 
Lem~oJT, S J; Fuller, D J; Booth, B.2; Rahman, A.2; Gobbm% ft.:; Lai, 
A. ~ 1. Orpha'~7 Medical, bzc., Mi~metotlka, ll4N,. 2. CeJTt~-e for D~Ttg 
Evaktation m~d Research, Food aJzd Drug Admhzist~'ation, Rockville, 
MD; 3. CPKD Sohttio~Ts, Resea~'ch Triangle Park, NC. 
PURPOSE: A clinical trial of 1VBU (BuCy4) in 24 peds used 
initial IVBU doses of 1.0 or 0.8mg/kg for ages < 4y or >4y, respec- 
tively Q.6 hrs x 4 days. Full pharmacokinetic (PK) profiling and a 
single dose adjustment (when necessary) were used to target SE to 
900 - 1350 raM.rain. This full-sampling approach allowed ~90% 
patients to achieve target SE at steady state. The purpose was to 
further analyze these data to refine the dosing strategy and to 
develop a LSS to achieve the target 1VBU SE. METHODS: PK 
modeling yielded a 2-dose level mg/kg regimen: <= 12 kg dosed at 
1.1 mg/kg, >12 kg dosed at 0.8 mg/kg. Modeled area-under-the- 
curve data (AUC) for Doses 1 and 9 were compared to AUC esti- 
mated from a LSS. The LSS used 3 time-points for Dose 1 (2hr - 
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end of infusion, 4 hr and 6 hr) with the addition of a trough level 
for Dose 9 calculation. LSS AUC were calculated by: AUCinf = 
AUC0-6hr + AUCext, where AUC0-6hr was estimated using the 
linear trapezoidal rule and AUCext was computed by the ratio of 
the busulfan concentration at Hr 6 and the elimination rate con- 
stant, lz.. RESULTS: The LSS AUC showed good correlation 
with the full Dose i AUC (r2=0.96) and Dose 9 AUC (r2=0.97). 
For Dose 1 and Dose 9 AUCs, 22/24 and 23/23 peds had differ- 
ences of <10% calculated by the LSS, respectively. CONCLU-  
SIONS: The LSS accurately predicted 1VBU SE. Using a dosing 
strategy" of 1.1 mg/kg for <12 kg and 0.8 mg/kg for >12kg patients, 
clinical application of this approach should effcctively guide dose 
adjustment and SE targeting in peds. 
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION SUCCESS- 
FULLY CORRECTS CONGENITAL IMMUNODEFICIENCY SYNDROMES 
Km'tzl, erg, J.; Szabolcs, P.; Driscoll, T.; M,stafa, M.; Arcbamba,lt, 
B.; ~llartM, P.L. Pediatric.r, D~ke University Medical Celtter, 
Din'ham, NC. 
Pediatric patients with congenital Jmmunodeficiency s ndromes 
die early in life. Allogeneic stem cell transplantation (SCT) is cura- 
tive, but many pts lack a suitably matched living related or unrelated 
donor. Some children lacking matched onors have been transpIant- 
ed with T cell depleted haplo-identical stem cells from a parent, but 
despite ngTaftment of donor T-cells, only 3 0% of these pts reconsti- 
tute B-cells. Unrelated cord blood (UCB) is a source of allogeneic 
donor cells that can he used without full HLA matching. We report 
our results using UCB transplantation after myeloablative 
chemotherapy (busulfan/cytoxan/ATG) as primary therapy for 25 
pediatric pts with various congenital immunodeficiency syndromes 
over the past 7 years. Pts ranged in age from 4 months to 4 years and 
were diagnosed with SCID (n=3), CID (6), Leukocyte adhesion defi- 
ciency (1), Familial erythropahgocytic lymphohistiocytosis (4), Wis- 
cott Aldrich Syndrome (10), and PNP Deficiency (1). They were 
transplanted with grafts matching at 3 (11=1), 4 (11), 5 (8) or 6 (1) 
HLA loci. Grafts delivered higher cell doses than typically seen with 
UCB grafts because the pts were small. The median cell dose was 
10.38 x 10e7 cells/kg containing 5.94 x 10e5 CD34 cells/kg. 
Cyclosporine and solmnedrol were given for GvItD prophylaxis. 
Engraftment of neutrophils (ANC 500/nL) occurred in all pts in a 
median of 18 days (range 7-45) and of platelets (nntransfilsed cotmt 
of 50K/uL) in 67 days (range 31-189). Grades II-IV acute GvHD 
developed in 4 pts and limited chronic GvHD of the skin developed 
in all surviving pts with WAS and 2 pts with CID. Five patients died 
of infection (n=3), EBV-LPD with cGvI iD (n=l) or VOD 
(n=l)within the first few months post transplant. The remaining 
patients are surviving with 100% chimeric grafts for a median of 4 
years with full T and B cell immune reconstimtion. Surviving pts 
have been successfially immunized with ldlled and live vaccines and 
have not encountered late opportunistic nfections. W'e conclude that 
UCB is particularly suited for patients with congenital imlnm~odefi- 
ciency syndromes. They experience faster engraftment and low prob- 
abilities of severe GvHD. UCB transplantation should be considered 
for all such patients lacking a matched related stem cell donor. 
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PHARMACOKINETIC STUDY OF RABBIT ANTI-THYMOCYTE GLOBULIN 
IN CHILDREN UNDERGOING BONE MARROW TRANSPLANTATION 
673a*Tg, C.Y; Cowing, M.J.; Zbang, L.Q.; Abramovitz, L.; Toomey, K.; 
Q,im2, M.A.; Horn, B.dM Pediatrics, UCSF, &t, Fl:nm'isco, Gd. 
Introduction: Pharmacokinetic data of rabbit ATG in children 
receiving bone marrow transplantation, especially in relation to 
engraftment and the development of acute GVHD, is lacking. We 
report our preliminary results on five children using rabbit ATG 
as part of the conditioning regimen. Patients underwent bone 
marrow transplantation between March and July of 2002. We fol- 
lowed the sermn rabbit ATG levels (reported as the percent of 
rabbit ATG remaining up to six months post transplantation), 
engraftment, and incidence of acute GVHD. Method: All patients 
received a conditioning regimen that included busulfan, fludara- 
bine and rabbit ATG. Four doses of rabbit ATG, 0.Smg/kg on day 
-4 and 2.5mg/kg on days ~3 to -1, for a total dose of 8mg/kg were 
given. Rabbit IgG serum level was deterntined by ELISA. The 
percent of rabbit ATG remaining after transplantation  days 7, 
14, 28 and monthly until six months post transplant was calculated 
based on rabbit IgG level detected on day 0. Result: Four patients 
had 6/6 matched unrelated BMT donors, and one patient had 
matched related donor. The  diagnosis included SCID (n-2), 
Hnrler's syndrome (n=l), CML (n-i),  and Clnediak-Iligashi dis- 
ease (n=l). The median age was 2.4 years (range from 1 to 5 years) 
at the time of transplantation. All patients engrafted with a median 
time to engraftment of 20 days ranging ftom 18 to 24 days. Only 
one patient (no.5) developed cutaneous acute GVHD (grade II) 
on day +42. The percentage of rabbit ATG remaining post trans- 
plantation for all patients is shown in Table 1. Rabbit ATG was 
detected in all five patients up to 100 days post transplantation a d 
in 4/4 patients at I60 days post transplant. Campbell et al. detect- 
ed rabbit IgG in nlost of 79 adults patients for more than 90 days 
after transplantation. In our study, rabbit ATG can be detected 
even after 160 days post transplantation in all patients tested. The 
incidence of acute GVHD in this limited cohort was low. We 
continue to enroll patients into the study to assess if the post 
transplant seruln rabbit ATG levels can affect the incidence of 
acute GVHD. Table 1 Presents the % of Rabbit ATG remaining 
in sermn post-transplant, compared to level on day 0 
da~ + day 1146r]daY da} 10fl ; day day 1/ 28 +4O +6~ I~  150 160 170 19n 
...... I I "£!: : . . . . . . . . . . . . .  
. . . . . . . . . . . .  . . . . . . .  j 
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PHARMACOKINETICS OF IV BUSULFAN (IV BU) IN PEDIATRIC 
INFANTS (< IO-KILOGRAM BODY WEIGHT) UNDERGOING STEM 
CELL TRANSPLANT 
Dalle, ft.1; ~'fgdl, D.:; Daval, M.1; Tbeoret, }:s; Tto,lor, C.-'; f'~t~/~oJ~, 
M. 1; 3/ioghrabi, A.I; La1"ocq,e, D.I; ChampagTze, M.A.1 1. hematology 
alzd oncol%[y, Sai*lte ff lsti,e Hospit,d, Molm'eal, QC, Ca',ada; 
2. Methodist Chilc~re, 's Hospital of So~M~ Texas, Nz, A,tor~io, TX. 
Busulf:an is an important component of myeloablative regimens 
for patients undergoing HSC transplantation. Use of oral busulfan 
is limited by a wide inter-patient and intra-patient variability in 
disposition. A parenteral form was developed to overcome these 
difficulties. For pediatric patients, a posology of 0.8 (children >3 
years) to 1.0 mg/kg (children <3 years) x 16 has been suggested 
(Wall, ASH 2000). However, limited information is available on 
its use in small children. We therefore retrospectivally studied 
pharmaco~netics of IV Bu (Busulfex@, Orphan Medical) in 14 
children < 1 year of age and < 10 kg (median age 4.8 months, 
median weight 5.9 kg) undergoing stem cell transplantation for 
severe combined immunodeficiency (n=6), hematological malig- 
nancies (n-3), inherited syndrome (n=3) or other (n=2). Drug was 
initially given at 1 mg/kg/dose (2 hour-infilsion) every 6 hours x 
16 doses (initial dosing was 0.8 mg/kg/dose in 3). Serial blood 
specimens were obtained and plasma busulfan values were deter- 
mined by HPLC.  The target AUC was 600-900 btMol.mn for 
patients with sibling donor and 900-1300 for the others. Main 
clinical characteristics and pharmacological results are summa- 
rized in table 1. Dose adjustment was subsequently made accord- 
ing to the initial results. IV Bu dose was decreased in 7, 
unchanged in 5 and increased in 2. Only one patient received 
more than the intended 16 mg/kg total dose. Median total dose 
given in this cohort was 13.8 mg/kg. One patient experienced a 
severe VOD. Donor engraftment was documented in 100% of 
patients. Conclusion: use of IV Bu in infants is safe but pharmaco- 
kinetic guided dose adjustment appears necessary. The current 
recommended ose of Img/kg/dose for children under 3 years 
appears to be associated with dosage higher than targeted. 
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